Home > News > featured news > Vow Inc. joins portfolio of K1, a leading investment firm focusing on high-growth software companies globally

PHARMA TECH

Vow Inc. joins portfolio of K1, a leading investment firm focusing on high-growth software companies globally

Digital Pharmacist | October 11, 2021

Vow, a leading provider of interactive phone systems to the pharmacy industry, announced its strategic partnership with Digital Pharmacist, a software company that powers digital communication and adherence solutions for over 7,000 pharmacies. Together, the combined businesses establish an industry leading portfolio of solutions that automate pharmacy operations and enhance patient communications through its core solutions: Patient Engagement Platform, interactive voice response (IVR), website, and mobile app.

We are thrilled to partner with Digital Pharmacist, it's an exciting opportunity to further expand our offerings and build innovative products, This next chapter of growth will accelerate our business and development, allowing our current customers and the rest of the pharmacy industry to experience the benefits. We remain highly committed to the pharmacy community and see that the Digital Pharmacist team shares the same level of commitment.

- Chip Simmons, the founder of Vow, who will lead the combined IVR business.


Vow will continue to offer its best-in-class IVR technology platform. It will subsume Digital Pharmacist's IVR operations and products, migrating the company's customers to Vow's platform in 2022. Digital Pharmacist will subsume Vow's website and mobile app solutions, augmenting these products with new features and functionality that will enrich patient engagement and experience.

We are excited to partner with Chip and the Vow team to bring the Vow brand and products to a greater number of independent pharmacies, Digital Pharmacist's strategic combination with Vow positions us to deliver best-in-class interoperable IVR, website, and mobile app products to our pharmacy customers and their patients. Our next-generation Patient Engagement Platform will form the cornerstone of our product platform.

- Corey Hansen, CEO of Digital Pharmacist.

About Vow
Vow, headquartered in Boiling Springs, South Carolina, is a leading provider of interactive phone systems to the pharmacy industry where its solutions operate in nearly two-thousand pharmacies. The company's products automate operations, improve pharmacists' productivity, and improve patient experience.

About Digital Pharmacist
Digital Pharmacist, headquartered in Austin, Texas, is a leading provider of software to the pharmacy industry where its solutions are deployed across more than seven thousand pharmacies. The company's products drive patient engagement and improve patient outcomes.

Spotlight

Towards a new EU pharmaceutical strategy

As the European Commission prepares to launch a much awaited revised EU pharmaceutical strategy, two recent studies by the European Parliament's Panel for the Future of Science and Technology.

More featured news

Spotlight

Towards a new EU pharmaceutical strategy

As the European Commission prepares to launch a much awaited revised EU pharmaceutical strategy, two recent studies by the European Parliament's Panel for the Future of Science and Technology.

Related News

PHARMA TECH

Douglas Pharmaceuticals Forms Lead Program R-107 Clinical Advisory Board

Douglas Pharmaceuticals | January 27, 2023

A clinical advisory board has been established to support Douglas Pharmaceuticals' lead program R-107, an oral extended-release dose of racemic ketamine being developed as an adjunctive or stand-alone therapy for treatment-resistant depression. Douglas Pharmaceuticals is a New Zealand-based pharmaceutical company specializing in the development of specialty generic and repurposed medications (TRD). Peter Surman, Chief Scientific Officer expressed, "We are very excited to bring together a group of world-class experts in the field of psychiatry, to help guide our late-stage development of R-107." "We believe their deep knowledge in the field, insights and contributions will be instrumental in charting an efficient course through pivotal clinical studies in TRD," he added. (Source – Cision PR Newswire) Some of the members of the clinical advisory board are as follows: • Prof. Paul Glue [MB, ChB (Otago), MD (Bristol), FRCPsych] • Prof. Alan F. Schatzberg, [MD] • Prof. Sanjay J. Mathew [MD] • Prof. Allan Young [MB, ChB, MPhil, Ph.D., FRCP (Edin.), FRCPC, FRCPsych] • Prof. Wiesław J. Cubała, [MD, PhD] • Prof. Colleen Loo [MBBS (Hons), FRANZCP, MD] About Douglas Pharmaceuticals New Zealand's largest private pharmaceutical and healthcare firm, Douglas Pharmaceuticals, employs over 700 people and exports to over 40 countries. The company provides creative, competitive, and high-quality healthcare solutions to 'improve lives'. It designs, manufactures, and distributes unique and generic products, preferring those with significant intellectual property and technological complexity in high-unmet need sectors. The company's presence in international markets continues to grow, exposing New Zealand to the world. It is dedicated to improving people's health all around the globe. Some of the products that the company works with cutting-edge partners to develop, make, market, and distribute are pharmaceuticals, nutraceuticals, automated compliance systems, and consumer healthcare items.

Read More

RESEARCH, PHARMA TECH

AskBio Receives EC Orphan Drug Designation for AB-1003 via BrainVectis

Asklepios BioPharmaceutical, Inc. (AskBio) | March 01, 2023

Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, recently announced that the European Commission (EC) has granted orphan drug designation to AB-1003 (also known as LION-101) for the treatment of limb-girdle muscular dystrophy (LGMD). AB-1003 is an investigational recombinant adeno-associated virus (AAV) based gene therapy that is being developed as a one-time intravenous infusion for patients with LGMD type 2I/R9. The disease affects 4.5 people per million worldwide, with more than 5,000 people affected in the EU and the US. The EC decision was received through AskBio's EU-based subsidiary BrainVectis, following a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) AB-1003 is currently being investigated in a Phase 1/2 multicenter study in the US to evaluate its tolerability, safety, and efficacy in adult subjects with genotypically confirmed LGMD2I/R9. The EC for medicinal products grants orphan drug designation developed to treat a life-threatening disease that affects no more than five people in 10,000 in the EU, provided there is no other adequate treatment option or the medicine can bring significant value to those affected by a specific condition. This designation will provide special incentives in the EU, including eligibility for protocol assistance and possible reductions or exemptions in certain regulatory fees. Additionally, if the medicine is approved for marketing, this designation will provide ten years of marketing exclusivity. Limb-girdle muscular dystrophy (LGMD) is a group of diseases that cause progressive weakening and wasting of the muscles in the arms and legs. The severity, features of LGMD and age of onset vary among the many subtypes of the condition and are often inconsistent, even within the same family. Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) is a form of LGMD caused by mutations in the FKRP gene. Signs and symptoms of LGMD2I/R9 often appear in late childhood and may include difficulty walking and running. The symptoms intensify with time, eventually leading to considerable disability, and afflicted persons typically require a wheelchair for movement roughly 23-26 years after beginning. Unfortunately, there is presently no treatment that slows the advancement of the disease, and management is based on the indications and symptoms that each individual exhibits. About Asklepios BioPharmaceutical, Inc. (AskBio) AskBio is a leading, fully integrated gene therapy company dedicated to developing innovative gene therapeutics and life-saving medicines. With operations worldwide, its pipeline includes gene therapy candidates for various diseases, including the central nervous system, neuromuscular, metabolic, and cardiovascular diseases. AskBio's global headquarters are located in RTP, NC, with European headquarters in Edinburgh. In addition, the company operates AAV research centers in Philadelphia, PA; Columbus, OH; and Paris, and modern clinical and commercial facilities in San Sebastian, Spain.

Read More

BUSINESS INSIGHTS, PHARMACY MARKET

Envision Pharma Group Announces Acquisition of OKRA.ai

Envision Pharma Group | February 10, 2023

Envision Pharma Group (Envision), a leading evidence-based communication services and industry-leading technology solutions provider serving biotech, pharmaceutical, and medical device companies recently announced the acquisition of OKRA.ai, a leading technology company active in the development of artificial intelligence (AI) solutions for commercialization, medical, real-world evidence and data analytics, and pricing for the life sciences and pharmaceutical industries. OKRA.ai's AI products and solutions transform enormous scientific, clinical, and commercial data sets into actionable insights for customers in the health sciences industry, empowering decision-making and driving action. Dr. Loubna Bouarfa, the founder of OKRA.ai, will join the Executive Leadership Team of Envision. Loubna recently received the renowned Deloitte Fast 50 Women in Leadership Award as well as the Forbes 50 Top Women in Tech. OKRA.ai has offices in the United Kingdom and the Netherlands and employs around 30 people. With the purchase of OKRA.ai, Envision Pharma Group will have over 1,400 employees spread across four continents. Envision Pharma Group's CEO Meg Heim commented, "We are delighted to welcome OKRA.ai into the Envision Pharma Group family." She added, "The acquisition of OKRA.ai marks an exciting milestone in Envision's evolution as we continue to accelerate and deliver a compelling combination of technology-enabled capabilities and solutions to clients. The combination of Envision's leading technology, capabilities, and solutions with OKRA.ai's artificial intelligence solutions and expertise enables us to strengthen our offerings to clients across the product life cycle, but more importantly, support patients in their journey to health and wellness." (Source – Globe Newswire) About Envision Pharma Group Founded in 2001, Envision is a leading evidence-based communication service and industry-leading technology solutions provider serving biotech, pharmaceutical, and medical device companies. It works with over 200 pharmaceutical and biotech firms, including 18 of the top 20 pharmaceutical firms. The company began by reinventing how biopharma companies managed their global data communications programs by leveraging smart technology and best-in-class publication planning. It has since grown to become a leading provider of healthcare communications services and medical affairs technology solutions. It assists clients throughout the pharmaceutical product lifecycle, establishing solid partnerships and gaining client trust in purpose-built solutions.

Read More

PHARMA TECH

Douglas Pharmaceuticals Forms Lead Program R-107 Clinical Advisory Board

Douglas Pharmaceuticals | January 27, 2023

A clinical advisory board has been established to support Douglas Pharmaceuticals' lead program R-107, an oral extended-release dose of racemic ketamine being developed as an adjunctive or stand-alone therapy for treatment-resistant depression. Douglas Pharmaceuticals is a New Zealand-based pharmaceutical company specializing in the development of specialty generic and repurposed medications (TRD). Peter Surman, Chief Scientific Officer expressed, "We are very excited to bring together a group of world-class experts in the field of psychiatry, to help guide our late-stage development of R-107." "We believe their deep knowledge in the field, insights and contributions will be instrumental in charting an efficient course through pivotal clinical studies in TRD," he added. (Source – Cision PR Newswire) Some of the members of the clinical advisory board are as follows: • Prof. Paul Glue [MB, ChB (Otago), MD (Bristol), FRCPsych] • Prof. Alan F. Schatzberg, [MD] • Prof. Sanjay J. Mathew [MD] • Prof. Allan Young [MB, ChB, MPhil, Ph.D., FRCP (Edin.), FRCPC, FRCPsych] • Prof. Wiesław J. Cubała, [MD, PhD] • Prof. Colleen Loo [MBBS (Hons), FRANZCP, MD] About Douglas Pharmaceuticals New Zealand's largest private pharmaceutical and healthcare firm, Douglas Pharmaceuticals, employs over 700 people and exports to over 40 countries. The company provides creative, competitive, and high-quality healthcare solutions to 'improve lives'. It designs, manufactures, and distributes unique and generic products, preferring those with significant intellectual property and technological complexity in high-unmet need sectors. The company's presence in international markets continues to grow, exposing New Zealand to the world. It is dedicated to improving people's health all around the globe. Some of the products that the company works with cutting-edge partners to develop, make, market, and distribute are pharmaceuticals, nutraceuticals, automated compliance systems, and consumer healthcare items.

Read More

RESEARCH, PHARMA TECH

AskBio Receives EC Orphan Drug Designation for AB-1003 via BrainVectis

Asklepios BioPharmaceutical, Inc. (AskBio) | March 01, 2023

Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, recently announced that the European Commission (EC) has granted orphan drug designation to AB-1003 (also known as LION-101) for the treatment of limb-girdle muscular dystrophy (LGMD). AB-1003 is an investigational recombinant adeno-associated virus (AAV) based gene therapy that is being developed as a one-time intravenous infusion for patients with LGMD type 2I/R9. The disease affects 4.5 people per million worldwide, with more than 5,000 people affected in the EU and the US. The EC decision was received through AskBio's EU-based subsidiary BrainVectis, following a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) AB-1003 is currently being investigated in a Phase 1/2 multicenter study in the US to evaluate its tolerability, safety, and efficacy in adult subjects with genotypically confirmed LGMD2I/R9. The EC for medicinal products grants orphan drug designation developed to treat a life-threatening disease that affects no more than five people in 10,000 in the EU, provided there is no other adequate treatment option or the medicine can bring significant value to those affected by a specific condition. This designation will provide special incentives in the EU, including eligibility for protocol assistance and possible reductions or exemptions in certain regulatory fees. Additionally, if the medicine is approved for marketing, this designation will provide ten years of marketing exclusivity. Limb-girdle muscular dystrophy (LGMD) is a group of diseases that cause progressive weakening and wasting of the muscles in the arms and legs. The severity, features of LGMD and age of onset vary among the many subtypes of the condition and are often inconsistent, even within the same family. Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) is a form of LGMD caused by mutations in the FKRP gene. Signs and symptoms of LGMD2I/R9 often appear in late childhood and may include difficulty walking and running. The symptoms intensify with time, eventually leading to considerable disability, and afflicted persons typically require a wheelchair for movement roughly 23-26 years after beginning. Unfortunately, there is presently no treatment that slows the advancement of the disease, and management is based on the indications and symptoms that each individual exhibits. About Asklepios BioPharmaceutical, Inc. (AskBio) AskBio is a leading, fully integrated gene therapy company dedicated to developing innovative gene therapeutics and life-saving medicines. With operations worldwide, its pipeline includes gene therapy candidates for various diseases, including the central nervous system, neuromuscular, metabolic, and cardiovascular diseases. AskBio's global headquarters are located in RTP, NC, with European headquarters in Edinburgh. In addition, the company operates AAV research centers in Philadelphia, PA; Columbus, OH; and Paris, and modern clinical and commercial facilities in San Sebastian, Spain.

Read More

BUSINESS INSIGHTS, PHARMACY MARKET

Envision Pharma Group Announces Acquisition of OKRA.ai

Envision Pharma Group | February 10, 2023

Envision Pharma Group (Envision), a leading evidence-based communication services and industry-leading technology solutions provider serving biotech, pharmaceutical, and medical device companies recently announced the acquisition of OKRA.ai, a leading technology company active in the development of artificial intelligence (AI) solutions for commercialization, medical, real-world evidence and data analytics, and pricing for the life sciences and pharmaceutical industries. OKRA.ai's AI products and solutions transform enormous scientific, clinical, and commercial data sets into actionable insights for customers in the health sciences industry, empowering decision-making and driving action. Dr. Loubna Bouarfa, the founder of OKRA.ai, will join the Executive Leadership Team of Envision. Loubna recently received the renowned Deloitte Fast 50 Women in Leadership Award as well as the Forbes 50 Top Women in Tech. OKRA.ai has offices in the United Kingdom and the Netherlands and employs around 30 people. With the purchase of OKRA.ai, Envision Pharma Group will have over 1,400 employees spread across four continents. Envision Pharma Group's CEO Meg Heim commented, "We are delighted to welcome OKRA.ai into the Envision Pharma Group family." She added, "The acquisition of OKRA.ai marks an exciting milestone in Envision's evolution as we continue to accelerate and deliver a compelling combination of technology-enabled capabilities and solutions to clients. The combination of Envision's leading technology, capabilities, and solutions with OKRA.ai's artificial intelligence solutions and expertise enables us to strengthen our offerings to clients across the product life cycle, but more importantly, support patients in their journey to health and wellness." (Source – Globe Newswire) About Envision Pharma Group Founded in 2001, Envision is a leading evidence-based communication service and industry-leading technology solutions provider serving biotech, pharmaceutical, and medical device companies. It works with over 200 pharmaceutical and biotech firms, including 18 of the top 20 pharmaceutical firms. The company began by reinventing how biopharma companies managed their global data communications programs by leveraging smart technology and best-in-class publication planning. It has since grown to become a leading provider of healthcare communications services and medical affairs technology solutions. It assists clients throughout the pharmaceutical product lifecycle, establishing solid partnerships and gaining client trust in purpose-built solutions.

Read More

More featured news